{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:18:23Z","timestamp":1786994303883,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7192218"],"award-info":[{"award-number":["7192218"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242210"],"award-info":[{"award-number":["7242210"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.molimm.2024.09.008","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T06:39:31Z","timestamp":1726814371000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["IL-17A activates JAK\/STAT signaling to affect drug metabolizing enzymes and transporters in HepaRG cells"],"prefix":"10.1016","volume":"175","author":[{"given":"Yuanyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2024.09.008_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","article-title":"Functional specialization of interleukin-17 family members","volume":"34","author":"Iwakura","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.molimm.2024.09.008_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.molimm.2024.09.008_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","article-title":"Secukinumab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.molimm.2024.09.008_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2024.09.008_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1476-4598-10-150","article-title":"IL-17 induces AKT-dependent IL-6\/JAK2\/STAT3 activation and tumor progression in hepatocellular carcinoma","volume":"10","author":"Gu","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.molimm.2024.09.008_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.molimm.2024.09.008_bib9","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1002\/ptr.7155","article-title":"Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23\/Th17 axis via regulating Jak2\/Stat3 signaling pathway","volume":"35","author":"Zhang","year":"2021","journal-title":"Phytother. Res."},{"issue":"6","key":"10.1016\/j.molimm.2024.09.008_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12727","article-title":"The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases","volume":"88","author":"Gao","year":"2018","journal-title":"Scand. J. Immunol."},{"issue":"5","key":"10.1016\/j.molimm.2024.09.008_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/cells12050770","article-title":"Okadaic acid activates JAK\/STAT signaling to affect xenobiotic metabolism in HepaRG Cells","volume":"12","author":"Wuerger","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.taap.2011.03.019","article-title":"The effect of interferon-\u03b1 on the expression of cytochrome P450 3A4 in human hepatoma cells","volume":"253","author":"Flaman","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.molimm.2024.09.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","article-title":"Drug metabolism in the liver","volume":"21","author":"Almazroo","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molimm.2024.09.008_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.03.030","article-title":"IL-17A \u2013 a regulator in acute inflammation: Insights from in vitro, in vivo and in silico studies","volume":"139","author":"Sud","year":"2021","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.molimm.2024.09.008_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib16","first-page":"133","article-title":"Novel patents targeting interleukin-17A; implications in cancer and inflammation","volume":"13","author":"Santibanez","year":"2018","journal-title":"Recent Pat. Anti-canc"},{"issue":"7","key":"10.1016\/j.molimm.2024.09.008_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.2012.685159","article-title":"The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human","volume":"8","author":"Andersson","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.molimm.2024.09.008_bib18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cpt.1434","article-title":"Pharmacodynamic drug-drug interactions","volume":"105","author":"Niu","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.molimm.2024.09.008_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/14740338.2012.631910","article-title":"Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions","volume":"11","author":"Magro","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/toxsci\/kfx290","article-title":"Cellular and molecular effects of prolonged low-level sodium arsenite exposure on human hepatic HepaRG cells","volume":"162","author":"Dreval","year":"2018","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cei.13140","article-title":"Synergistic effect of interleukin-17 and tumour necrosis factor-\u03b1 on inflammatory response in hepatocytes through interleukin-6-dependent and independent pathways","volume":"193","author":"Beringer","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.molimm.2024.09.008_bib22","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.106.010033","article-title":"Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes","volume":"34","author":"Jigorel","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.molimm.2024.09.008_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10735-022-10086-6","article-title":"JAK-STAT signaling mediates the senescence of cartilage-derived stem\/progenitor cells","volume":"53","author":"Ji","year":"2022","journal-title":"J. Mol. Histol."},{"issue":"1","key":"10.1016\/j.molimm.2024.09.008_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1208\/s12248-019-0395-x","article-title":"Impact of interleukin-6 on drug-metabolizing enzymes and transporters in intestinal cells","volume":"22","author":"Simon","year":"2019","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.molimm.2024.09.008_bib25","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3892\/ijmm.2016.2710","article-title":"p43 induces IP-10 expression through the JAK-STAT signaling pathway in HMEC-1 cells","volume":"38","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"12","key":"10.1016\/j.molimm.2024.09.008_bib26","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/17425250903304056","article-title":"Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines","volume":"5","author":"Fardel","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.molimm.2024.09.008_bib27","first-page":"207","article-title":"Regulation of cytochrome p450 by inflammatory mediators: why and how?","volume":"29","author":"Morgan","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"43,Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.molimm.2024.09.008_bib29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hep.510240407","article-title":"Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin","volume":"24","author":"Fromm","year":"1996","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.molimm.2024.09.008_bib30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2125.2008.03120.x","article-title":"The recovery time-course of CYP3A after induction by St John\u2019s wort administration","volume":"65","author":"Imai","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","article-title":"Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.","volume":"76","author":"Faber","year":"2004","journal-title":"Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1530-0277.1995.tb01516.x","article-title":"Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase","volume":"19","author":"Lucas","year":"1995","journal-title":"Alcohol Clin. Exp. Res"},{"issue":"2","key":"10.1016\/j.molimm.2024.09.008_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/dmd.117.078048","article-title":"The JAK1\/2 inhibitor ruxolitinib reverses interleukin-6-mediated suppression of drug-detoxifying proteins in cultured human hepatocytes","volume":"46","author":"Febvre-James","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.molimm.2024.09.008_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106439","article-title":"Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells","volume":"83","author":"Le V\u00e9e","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.molimm.2024.09.008_bib35","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.bcp.2010.08.005","article-title":"IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways","volume":"80","author":"Wang","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.molimm.2024.09.008_bib36","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-013-1042-3","article-title":"Extra-Hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling","volume":"30","author":"Kacevska","year":"2013","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.molimm.2024.09.008_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/dmd.117.078675","article-title":"Regulation of drug metabolism by the interplay of inflammatory signaling, steatosis, and xeno-sensing receptors in HepaRG cells","volume":"46","author":"Tanner","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.molimm.2024.09.008_bib38","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1096\/fj.14-258780","article-title":"Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease","volume":"28","author":"Velenosi","year":"2014","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.molimm.2024.09.008_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2174\/1874467215666220823123852","article-title":"Scutellarin mediates cytochrome P450 3A4 and 2C19 expression via pregnane X receptor and constitutive androstane receptor","volume":"16","author":"Huang","year":"2023","journal-title":"Curr. Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.molimm.2024.09.008_bib40","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/cpt.1558","article-title":"Secukinumab treatment does not alter the pharmacokinetics of the cytochrome P450 3A4 substrate midazolam in patients with moderate to severe psoriasis","volume":"106","author":"Bruin","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.molimm.2024.09.008_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamadermatol.2022.1609","article-title":"Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults","volume":"158","author":"Ruan","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.molimm.2024.09.008_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.intimp.2019.01.005","article-title":"Dual effect of T helper cell 17 (Th17) and regulatory T cell (Treg) in liver pathological process: From occurrence to end stage of disease","volume":"69","author":"Zhang","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.molimm.2024.09.008_bib43","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40262-022-01173-8","volume":"61","author":"Gatti","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.molimm.2024.09.008_bib44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","article-title":"A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J. Dermatol. Treat."},{"issue":"1","key":"10.1016\/j.molimm.2024.09.008_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2235040","article-title":"Pyoderma gangrenosum and Beh\u00e7et\u2019s-like disease induced by secukinumab: a paradoxical drug reaction","volume":"34","author":"Avc\u0131","year":"2023","journal-title":"J. Dermatol. Treat."},{"issue":"5","key":"10.1016\/j.molimm.2024.09.008_bib46","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1080\/09546634.2022.2062281","article-title":"The dark side of the moon: the immune-mediated adverse events of IL-17A\/IL-17R inhibition","volume":"33","author":"Messina","year":"2022","journal-title":"J. Dermatol. Treat."},{"issue":"5","key":"10.1016\/j.molimm.2024.09.008_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/1568026619666190123160406","article-title":"Prediction of drug-drug interactions related to inhibition or induction of drug-metabolizing enzymes","volume":"19","author":"Dmitriev","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.molimm.2024.09.008_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-13-7647-4_1","article-title":"Overview: role of drug transporters in drug disposition and its clinical significance","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med Biol."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589024001780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589024001780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:43:41Z","timestamp":1731001421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589024001780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"alternative-id":["S0161589024001780"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2024.09.008","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-17A activates JAK\/STAT signaling to affect drug metabolizing enzymes and transporters in HepaRG cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2024.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}